Follow-up
Further Outpatient Care
- A screening colonoscopy is recommended for all patients with ulcerative colitis 8-10 years after the onset of symptoms to rule out colonic neoplasia and to reclassify the extent of disease.
- Patients with extensive colitis or left-sided colitis with negative findings on screening colonoscopy should begin surveillance colonoscopy in 1-2 years.
- For patients with ulcerative colitis and primary sclerosing cholangitis, screening and subsequent surveillance colonoscopy begin on an annual basis at the time of onset of primary sclerosing cholangitis.
- Patients with proctosigmoiditis have no increased risk for colorectal cancer compared with the general population. However, these patients should be managed according to the current guidelines on colorectal cancer screening. See related CME at Guidelines Issued for Early Detection of Colorectal Cancer.
- If high-grade dysplasia or cancer is found, colectomy is performed.
- The management of low-grade dysplasia is controversial; however, most experts would recommend colectomy.
Complications
- Toxic megacolon occurs in less than 2% of cases and can be induced by hypokalemia, opiates, anticholinergics, and barium enemas. Patients are acutely ill. Conservative treatment can be tried for 24-48 hours with IV fluids, IV steroids, antibiotics, and IV cyclosporine. Patients may eventually require a total colectomy.
- The risk of colorectal cancer increases by 0.5-1% per year. Regular surveillance is needed.
Prognosis
- Most cases are controlled with medical therapies, with the patient experiencing lifelong exacerbations and remissions. In more severe cases, surgery results in a cure.
Patient Education
- For excellent patient education resources, visit eMedicine's Crohn Disease Center and Esophagus, Stomach, and Intestine Center. Also, see eMedicine's patient education articles Inflammatory Bowel Disease, Crohn Disease, and Crohn Disease FAQs.
- Additional information can be found at Crohn's & Colitis Foundation of America (CCFA).
Miscellaneous
Medicolegal Pitfalls
- Colonoscopy performed in patients with severely active disease can cause significant complications, such as perforation or toxic megacolon.
- Barium enemas performed in severe cases can precipitate toxic megacolon.
- Adverse effects due to medical therapy can be frequent; therefore, routine laboratory monitoring should be followed.
- Screening colonoscopy with subsequent surveillance colonoscopy should be initiated 8-10 years after the onset of symptoms of ulcerative colitis.
Special Concerns
- Pregnancy
- Sclerosing cholangitis and cholangiocarcinoma
- Extracolonic manifestations
More on Ulcerative Colitis |
| Overview: Ulcerative Colitis |
| Differential Diagnoses & Workup: Ulcerative Colitis |
| Treatment & Medication: Ulcerative Colitis |
Follow-up: Ulcerative Colitis |
| Multimedia: Ulcerative Colitis |
| References |
| « Previous Page | Next Page » |
References
Alcalde Encinas MM, Perez-Gracia A, Hallal H, et al. [Cerebral venous sinus thrombosis and ulcerative colitis]. Rev Esp Enferm Dig. Feb 2000;92(2):105-8. [Medline].
Brown MO. Inflammatory bowel disease. Prim Care. Mar 1999;26(1):141-70. [Medline].
Fichera A, Michelassi F. Indication for surgery: a surgeon's opinion. In: Sartor RB, Sandborn WJ. Kirsner's Inflammatory Bowel Diseases. 6th ed. New York: Saunders; 2004:596-601/39.
Froehlich F, Larequi-Lauber T, Gonvers JJ, et al. 11. Appropriateness of colonoscopy: inflammatory bowel disease. Endoscopy. Oct 1999;31(8):647-53. [Medline].
Hanauer SB. Inflammatory bowel disease. N Engl J Med. Mar 28 1996;334(13):841-8. [Medline].
Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. Mar 2005;11(3):314-21. [Medline].
Jayanthi V, Probert CS, Mayberry JF. Epidemiology of inflammatory bowel disease. Q J Med. Jan 1991;78(285):5-12. [Medline].
Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. Jan 2007;132(1):66-75; quiz 432-3. [Medline].
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. Jul 2004;99(7):1371-85. [Medline].
Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. Mar 2006;130(3):940-87. [Medline].
Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. Jun 2000;66(6):1863-70. [Medline].
Stenson WF, Korzenik J. Inflammatory bowel disease. In: Yamada T, ed. Textbook Of Gastroenterology. Vol 2. 4th ed. Philadephia: Lippincott Williams & Wilkins; 2003:1699-1759.
Thomas GA, Rhodes J, Green JT. Role of smoking in inflammatory bowel disease: implications for therapy. Postgrad Med J. May 2000;76(895):273-9. [Medline].
Tremaine WJ. Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol. Apr 2000;30(3):245-9. [Medline].
Further Reading
Keywords
ulcerative colitis, UC, inflammatory bowel disease, IBD, Crohn’s disease, Crohn disease, irritable bowel syndrome, IBS, colonic inflammation, rectal inflammation, toxic megacolon, ileus, diverticulitis, primary sclerosing cholangitis, rectal bleeding, bloody bowel movements
Follow-up: Ulcerative Colitis